| Company Name: |
cjbscvictory Gold
|
| Tel: |
13348960310 13348960310 |
| Email: |
3003867561@qq.com |
| Products Intro: |
Product Name:AstragalosideVI
CAS:84687-45-6
Purity:HPLC≥98% Package:5mg；10mg；20mg；50mg；100mg；200mg Remarks:5mg；10mg；20mg；50mg；100mg；200mg；500mg；1g
|
|
| | Astragaloside VI Basic information |
| Product Name: | Astragaloside VI | | Synonyms: | Astragaloside VI;(3beta,6alpha,16beta,20R,24S)-20,24-Epoxy-3-[(2-O-beta-D-glucopyranosyl-beta-D-xylopyranosyl)oxy]-16,25-dihydroxy-9,19-cyclolanostan-6-yl beta-D-glucopyranoside;β-D-Glucopyranoside, (3β,6α,16β,20R,24S)-20,24-epoxy-3-[(2-O-β-D-glucopyranosyl-β-D-xylopyranosyl)oxy]-16,25-dihydroxy-9,19-cyclolanostan-6-yl | | CAS: | 84687-45-6 | | MF: | C47H78O19 | | MW: | 947.11 | | EINECS: | | | Product Categories: | saponins | | Mol File: | 84687-45-6.mol |  |
| | Astragaloside VI Chemical Properties |
| density | 1.46±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 12.89±0.70(Predicted) |
| | Astragaloside VI Usage And Synthesis |
| Biological Activity | Astragaloside VI accelerates wound healing by activating the epidermal growth factor receptor/extracellular signal-regulated kinase (EGFR/ERK) signaling pathway. | | in vitro | Pretreatment with Astragaloside VI (AS-VI) at 1 μM increases EGFR activation in HaCaT cells. Astragaloside VI, a major intestinal metabolite of astragalosides, exerts the strongest EGFR activation. In HaCaT cells, the positive control, EGF expectedly results in 1.5±0.03-fold increase in cell proliferation, compared to the control. Astragaloside VI at the indicated concentrations also significantly promots cell proliferation in both HaCaT and HDF cells. Astragaloside VI promotes neural stem cell proliferation and enhances neurological function recovery in transient cerebral ischemic injury via activating EGFR/MAPK signaling cascades. | | in vivo | Astragaloside VI improves wound healing, compared to the control. In the simple noninfected wound model, wound healing in mice is accelerated by Astragaloside VI, where in the time required for wound closure is shortened by approximately 2-4 days , compared to that in the control group. Topical treatment with Astragaloside VI reduces the volume of pus produced, compared to the control group. Astragaloside VI treated wounds show an accelerated rate of healing, compared to the control and vaseline groups. By day 22, the Astragaloside VI -treated wounds fully close, whereas the blank and vaseline-treated wounds do not fully close until day 26. Angiogenesis is a crucial step in the formation of granulation tissue and wound healing. Astragaloside VI increases blood vessel formation in both the non -infected and infected wound models. Astragaloside VI could effectively activate EGFR/MAPK signaling cascades, promote NSCs proliferation and neurogenesis in transient cerebral ischemic br ains, and improve the repair of neurological functions in post-ischemic stroke rats. | | target | |
| | Astragaloside VI Preparation Products And Raw materials |
|